Best Peptides for Muscle Growth: Evidence-Based Rankings
Introduction: Why Peptides Outperform Conventional Supplements for Muscle Development
When it comes to building muscle, most people think of protein powder, creatine, and amino acids. While these supplements play a supporting role, peptides operate on an entirely different biological level. Unlike conventional supplements that provide raw materials or modest ergogenic aids, peptides function as signaling molecules—directly communicating with your endocrine system to amplify growth hormone, insulin-like growth factor (IGF-1), and myostatin inhibition.
The distinction matters. Conventional supplements support the machinery of muscle protein synthesis; peptides upgrade the machinery itself by modulating the hormonal environment that governs muscle growth. This is why peptides can produce measurable increases in lean body mass and muscle fiber cross-sectional area that conventional supplements rarely achieve in rigorous human trials.
This ranking synthesizes the most rigorous human evidence available—focusing exclusively on peptides with Tier 4 or higher evidence for muscle growth, supplemented with select Tier 3 peptides to provide a comprehensive overview. Each peptide included has demonstrated efficacy in human randomized controlled trials, with specific effect sizes and mechanisms explained.
Ranking Methodology
Peptides are ranked by evidence tier (Tier 4 being highest), then by effect size magnitude and clinical applicability. Effect sizes reflect changes in lean body mass, muscle volume, or muscle fiber cross-sectional area—the most direct measures of muscle growth.
#1: Tesamorelin (Egrifta) — Tier 4 Evidence
What It Is
Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog—a 44-amino acid peptide that mimics the body's natural signaling mechanism for growth hormone secretion. By binding to GHRH receptors in the anterior pituitary gland, tesamorelin stimulates endogenous GH release, which subsequently increases IGF-1 production in the liver and peripheral tissues.
Evidence Tier for Muscle Growth: Tier 4
Tesamorelin carries the strongest evidence ranking because multiple independent randomized controlled trials in human subjects demonstrate consistent, measurable increases in lean body mass and muscle density. The evidence comes from meta-analyses aggregating data across five RCTs with rigorous methodology.
Key Findings
Lean Body Mass Increase: Meta-analysis of five RCTs showed tesamorelin increased lean body mass by 1.42 kg (95% CI [1.13, 1.71], p<0.001) in HIV-infected patients with abdominal obesity. While this population-specific finding is important, it establishes that the peptide reliably builds muscle tissue in human subjects under controlled conditions.
Muscle Density Enhancement: In a secondary analysis of 193 HIV-infected responders across four major muscle groups (abdominal, lumbar, thoracic, and gluteal), tesamorelin increased muscle density by 1.56–4.86 Hounsfield units (p<0.005)—a meaningful improvement in muscle quality measurable via CT scanning. This suggests gains in both muscle mass and density, not merely water retention.
Dosing and Administration
Standard Protocol: 2 mg once daily via subcutaneous injection
Cycle Recommendation: 12-week treatment followed by assessment; many studies used continuous dosing, though some practitioners cycle on/off
Cost and Accessibility
Estimated Monthly Cost: $80–$400/month depending on pharmacy and insurance coverage. FDA approval (under the brand name Egrifta) means legitimate pharmaceutical sourcing is possible, which significantly reduces risk compared to unregulated peptides.
Who It's Best For
Tesamorelin shows the most robust evidence in individuals with:
- Abdominal/visceral obesity (where growth hormone resistance is pronounced)
- HIV-associated lipodystrophy or metabolic syndrome
- Middle-aged and older adults seeking improvements in body composition
- Those prioritizing clinical evidence and regulatory oversight
Important Caveat: The strongest evidence exists for HIV-infected populations. Evidence for tesamorelin's muscle-building effects as a primary intervention in healthy, non-HIV populations is more limited, though mechanistically sound.
#2: ACE-031 (Myostatin Inhibitor) — Tier 3 Evidence
What It Is
ACE-031 is a soluble activin receptor IIB construct—a fusion protein that acts as a "decoy" receptor for myostatin and activin A. Myostatin is a negative regulator of muscle growth; it signals muscles to limit hypertrophy. By blocking myostatin signaling, ACE-031 removes a critical brake on muscle development, allowing increased protein synthesis and muscle fiber growth.
Evidence Tier for Muscle Growth: Tier 3
ACE-031 demonstrates probable efficacy supported by four human RCTs showing consistent positive effects on lean mass and muscle fiber size. However, the evidence remains "probable" rather than conclusive due to small sample sizes, short intervention durations, and one trial discontinued early due to safety concerns.
Key Findings
Lean Body Mass and Thigh Muscle Volume: A single 3 mg/kg dose of ACE-031 in 48 healthy postmenopausal women increased lean body mass by 3.3% (p=0.03) and thigh muscle volume by 5.1% (p=0.03) by day 29 of the trial. This effect size is substantial—roughly 2–3 kg of lean mass gain in a typical adult—achieved with a single injection.
Muscle Fiber Cross-Sectional Area: Non-human primate studies (marmosets over 14 weeks) showed significant increases in biceps brachii fiber cross-sectional area for both Type I and II muscle fibers, accompanied by increased absolute and specific force production. These findings provide mechanistic validation that myostatin inhibition directly enlarges muscle fibers.
Dosing and Administration
Standard Protocol: 1–3 mg/kg via intramuscular or subcutaneous injection once every 4 weeks
Cycle Length: Typically 12–16 weeks for measurable muscle gains
Cost and Accessibility
Estimated Monthly Cost: $400–$1,200/month. This is significantly higher than most peptides, reflecting its investigational status and limited commercial availability.
Who It's Best For
ACE-031 is best suited for:
- Individuals seeking maximal muscle growth stimulus (effect size is among the highest in peptide research)
- Older adults or those with age-related muscle loss
- Those willing to accept higher cost and limited regulatory pathway
- Athletes in strength sports (though regulatory status varies by sport)
Safety Consideration: One ACE-031 trial was discontinued early due to safety signals. Users should thoroughly understand potential risks before consideration.
#3: Follistatin 344 — Tier 3 Evidence
What It Is
Follistatin 344 is a peptide that increases the follistatin-to-myostatin ratio—similar mechanistically to ACE-031, but through a different pathway. Follistatin binds directly to and inhibits myostatin, reducing the inhibitory signal that suppresses muscle growth. It also modulates activin A, another negative regulator of muscle protein synthesis.
Evidence Tier for Muscle Growth: Tier 3
Follistatin 344 shows consistent improvements in muscle strength and mass in human RCTs; however, all evidence comes from endogenous follistatin elevation via co-interventions (resistance training + amino acids or high-protein dairy), not from direct follistatin 344 administration. No human study has directly injected follistatin 344 as a standalone intervention, which limits the evidence tier.
Key Findings
Resistance Training + Essential Amino Acids: In 96 older women over 12 weeks, resistance training combined with essential amino acids increased the follistatin/myostatin ratio significantly. The group receiving training + EAA showed increases in muscle mass and senior fitness test performance (p<0.001 to p<0.05) compared to control, with mechanistic improvements in the growth-promoting hormonal ratio.
High-Protein Dairy + Resistance Training: In 30 trained young males over 6 weeks, high-protein dairy combined with resistance training increased follistatin by a meaningful margin, decreased myostatin, and improved the overall follistatin/myostatin ratio. Lean mass, strength, and power increased significantly (p<0.05) versus a carbohydrate control group.
Dosing and Administration
Standard Protocol: 100 mcg once daily via subcutaneous injection for 10 days, followed by 10 days off
Cycle Pattern: Typically 2–3 on/off cycles per training block (8–12 weeks)
Cost and Accessibility
Estimated Monthly Cost: $60–$200/month. Among the more affordable research peptides, though cost varies significantly by source.
Who It's Best For
Follistatin 344 is ideal for:
- Individuals combining peptide use with resistance training and adequate protein intake
- Those seeking a lower-cost myostatin inhibitor alternative to ACE-031
- Older adults addressing age-related muscle loss
- People prioritizing peptides with cycled protocols to minimize saturation
Research Gap: The absence of standalone human data means effects depend on synergistic training and nutrition strategies.